Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Final results for phase II study of R-1549 in gastric cancer

Nov. 10, 2003

Actimid enters phase II trial for prostate cancer

Nov. 3, 2003

Anti-EGFR antibody with ADCC-inducing activity

Oct. 31, 2003

Favrille raises financing to support phase II and III trials of FavId for NHL

Oct. 21, 2003

ACP-2127 advanced into preclinical testing

Oct. 20, 2003

Signal patent describes novel ER modulators for osteoporosis, cancer, etc.

Oct. 16, 2003

Evidence of antitumor activity for Xcellerated T-cells and IL-2 in renal cell carcinoma

Oct. 9, 2003

NeuTec seeks development partners for Mycograb for cancer

Oct. 8, 2003

Expansion of phase III Virulizin trial

Oct. 2, 2003

Telomerase-targeting vaccines in development at GemVax

Oct. 1, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...